Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - carmustine, quantity: 100 mg - injection, diluent for - excipient ingredients: ethanol absolute - carmustine-juno is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma 2. multiple myeloma - in combination with prednisone. 3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: croscarmellose sodium; macrogol 400; hypromellose acetate succinate; silicon dioxide; triacetin; purified talc; hyprolose; iron oxide red; magnesium stearate; titanium dioxide; microcrystalline cellulose; hypromellose - posaconazole dr.reddy's (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. ,posaconazole dr.reddy's is also indicated for the: ,? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

philips electronics australia ltd - 45232 - dental material, desensitizing resin - it is indicated for the relief of tooth sensitivity caused by root or nerve sensitivity due to thermal or chemical stimuli, periodontal conditions, gum recession, or dental bleaching. for use only by adults and children 6 years of age or older.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -